UNSPSC 51283904: Silvadene or silver sulfadiazine

This classification denotes a topical anti-infective agent and sulfonamide anti-infective agent with the molecular formula C10H9N4O2S.Ag, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W46JY43EJR, chemically known as sulfanilamide, n(sup 1)-2-pyrimidinyl-, monosilver(1+) salt but generally known as silver sulfadiazine, which bears US NIH Compound Identifier 31011. European Medicines Agency schedules Silver sulfadiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04622MIG.

World Health Organization schedules silver sulfadiazine in its Anatomical Therapeutic Chemical (ATC) Classification. Silvadene or silver sulfadiazine bears US NLM identifiers UMLS ID C0723179 and NCI Concept Code C66567. SMILES: C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+].

UNSPSC 51283904 Silvadene or silver sulfadiazine is a Commodity code that represents specialty pharmaceutical products. State and local governments procure this code infrequently and through indirect channels — the recent opportunities block shows no active solicitations for silver sulfadiazine itself. Instead, the two recent records tagged to this code involve unrelated pharmaceutical products: a completed Illinois Department of Public Health piggyback contract awarded to Chartwell Rx LLC for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) totaling $2,999,999.11 over three years, and a Seminole County, Florida IFB for Naloxone and drug deactivation systems. The mismatch between the code's nominal scope and the actual opportunities surfaced suggests this code sees limited relevant state and local activity, or that issuing bodies tag pharmaceutical procurements inconsistently.

No open solicitation for silver sulfadiazine or related burn-treatment topicals appears in the recent opportunities block. The Illinois award to Chartwell Rx LLC was completed on August 28, 2026, through the MMCAP Infuse cooperative purchasing vehicle — a common channel for state pharmaceutical procurement — but it does not match the code's stated product. Seminole County's July 2026 IFB, while tagged to this code, sought Naloxone and safe drug deactivation systems, again unrelated to silver sulfadiazine. Firms evaluating this code should monitor cooperative purchasing consortia such as MMCAP and state health department solicitations for topical burn and wound-care products, as activity under this specific code shows no current open demand in state and local markets.